Treatment outcomes of multidrug-resistant tuberculosis with chronic kidney/liver disease
Chiwook Chung, Jung Eun Shin, Doosoo Jeon, Hyungseok Kang, Jae‐Joon Yim, Kyung‐Wook Jo, Tae Sun Shim
European Respiratory Journal · 2022-06
Abstract
<b>Bedaquiline and delamanid are effective and might be safe in patients with chronic kidney or liver disease. MDR-TB patients with these comorbidities receiving bedaquiline and/or delamanid have poor treatment outcomes, probably owing to the comorbidities.</b> https://bit.ly/3NyDD15
MeSH terms
- Bedaquiline
- Medicine
- Tuberculosis
- Kidney disease
- Internal medicine
- Multiple drug resistance
- Multimorbidity
- Disease
- Chronic liver disease
- Intensive care medicine